Introduction

Needle‑free options now cover both everyday allergy control and the emergency treatment of anaphylaxis. This guide explains: (1) evidence‑based therapies for allergic rhinitis without injections (intranasal corticosteroids, combination antihistamine–steroid sprays, and sublingual immunotherapy), and (2) the role of epinephrine nasal spray alongside auto‑injectors for anaphylaxis.

Needle‑free daily control: intranasal medicines that work

• Intranasal corticosteroids (INCS) remain the preferred monotherapy for persistent allergic rhinitis. They outperform oral or intranasal antihistamines for global symptom control.

• When INCS alone are insufficient, a fixed‑dose combination of intranasal azelastine (antihistamine) plus fluticasone (steroid) provides additional benefit over either agent alone. Multiple RCTs and a meta‑analysis show superior reduction in Total Nasal Symptom Score vs monotherapy.

Practical notes

• INCS examples include fluticasone, mometasone, budesonide, and triamcinolone. Use daily, aiming the spray slightly outward (away from the septum) to reduce irritation.

• Combination azelastine–fluticasone can be considered second‑line when INCS alone do not control symptoms.

Needle‑free disease modification: sublingual immunotherapy (SLIT)

Allergen immunotherapy changes immune tolerance and can provide durable benefit after completion.

• FDA‑approved SLIT tablets (dissolve under the tongue) are available for:

• Grass: Grastek (timothy) and Oralair (5‑grass)

• Ragweed: Ragwitek

• House dust mite: Odactra (approved ages now 5–65 years in the US) These tablets are indicated for allergic rhinitis/rhinoconjunctivitis to the target allergen and have safety labeling that includes prescribing epinephrine in case of rare severe reactions.

• Custom‑mixed SLIT drops (multi‑allergen) are widely used in the U.S. as an off‑label option; clinical guidance highlights their favorable safety profile relative to injections, though they are not FDA‑approved. Shared decision‑making is recommended.

How Wyndly fits

• Wyndly offers both FDA‑approved tablets and personalized SLIT drops under physician supervision, delivered to the home with ongoing care. See Wyndly Immunotherapy and Allergy Drops for details.

Emergency treatment, needle‑free: epinephrine nasal spray

Epinephrine remains first‑line for anaphylaxis. The first non‑injection option—neffy (epinephrine nasal spray)—is FDA‑approved for emergency treatment of Type I allergic reactions, including anaphylaxis.

Key facts (United States; updated through November 13, 2025)

• Initial approval: August 9, 2024 for adults and children ≥30 kg (2 mg spray; single device delivers one dose). citeturn0search2turn0news13

• 2025 label expansion: March 5, 2025, FDA approved a 1 mg spray for pediatric patients 4 years and older weighing 15 to <30 kg. Availability announced May 7, 2025.

• Current U.S. dosing (per label):

• ≥30 kg: one 2 mg spray; if symptoms persist/worsen, repeat with a new device after 5 minutes.

• 15 to <30 kg: one 1 mg spray; if needed, repeat after 5 minutes. Patients should have immediate access to two devices. Seek emergency medical care after use. Absorption may be affected by structural/anatomical nasal conditions.

Clinical context

• Anaphylaxis guidelines still emphasize prompt epinephrine as first‑line therapy and historically specify intramuscular (IM) injection in the mid‑outer thigh; the nasal option adds a needle‑free route that may reduce treatment delays in selected patients. Regardless of route, rapid administration and availability of a second dose are critical.

Epinephrine nasal spray vs auto‑injectors (quick comparison)

Sources: FDA press materials and prescribing information; anaphylaxis practice parameter highlights. citeturn0search2turn0news13turn1search4turn1search2

Putting it together: a needle‑free plan

• For day‑to‑day rhinitis, start with INCS; escalate to azelastine–fluticasone if needed. Consider SLIT tablets (for grass, ragweed, dust mite) or physician‑directed SLIT drops to modify disease and reduce long‑term medication needs.

• For patients at risk of anaphylaxis, ensure immediate access to epinephrine (two doses). Discuss whether a nasal spray, an auto‑injector, or both best fit the situation, and build a written action plan with your clinician.

Wyndly can coordinate testing (40+ environmental allergens), personalized SLIT, and provide ongoing telehealth support. Learn more: Allergy Test, Immunotherapy.

FAQ

• Is epinephrine nasal spray a full replacement for my auto‑injector?

• It’s FDA‑approved for patients ≥4 years who weigh ≥15 kg. Choice of device should be individualized; many patients and clinicians may choose to carry the nasal spray, an auto‑injector, or both. Always have two doses and seek emergency care after treatment.

• How soon can I repeat a nasal dose?

• If symptoms persist or worsen, give a second spray after 5 minutes (using a new device).

• Do nasal steroids or antihistamine sprays help anaphylaxis?

• No. Use epinephrine immediately for anaphylaxis; intranasal therapies are for rhinitis control between reactions.

• Which SLIT options are FDA‑approved?

• Tablets for grass (Grastek, Oralair), ragweed (Ragwitek), and house dust mite (Odactra; ages 5–65). Custom liquid drops are off‑label in the U.S.

• Is combination azelastine–fluticasone really better than monotherapy?

• Yes, RCTs and a meta‑analysis show superior symptom reduction vs either agent alone.